Phase III long-term safety and efficacy of AGN-229666 in patients with seasonal or perennial allergic conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2018
At a glance
- Drugs AGN 229666 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.